Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 49.74M | 48.67M | 51.87M | 56.97M | 53.90M | 36.35M |
Gross Profit | 19.57M | 19.50M | 21.81M | 25.37M | 22.83M | 15.56M |
EBITDA | -2.52M | -6.88M | -7.97M | -6.16M | -6.73M | -6.08M |
Net Income | -5.45M | -8.91M | -9.57M | -7.55M | -5.22M | -6.33M |
Balance Sheet | ||||||
Total Assets | 31.59M | 29.14M | 34.44M | 42.29M | 48.69M | 27.97M |
Cash, Cash Equivalents and Short-Term Investments | 6.78M | 2.39M | 7.03M | 13.92M | 23.85M | 11.63M |
Total Debt | 5.07M | 4.64M | 2.75M | 1.77M | 2.66M | 4.19M |
Total Liabilities | 25.53M | 27.04M | 24.91M | 25.06M | 25.39M | 10.60M |
Stockholders Equity | 6.06M | 2.10M | 9.52M | 17.23M | 23.30M | 17.37M |
Cash Flow | ||||||
Free Cash Flow | -5.86M | -7.30M | -6.85M | -9.80M | 8.00M | -3.33M |
Operating Cash Flow | -5.86M | -7.29M | -6.75M | -9.52M | 8.22M | -3.24M |
Investing Cash Flow | -34.00K | -13.00K | -109.00K | -286.00K | -5.56M | -93.00K |
Financing Cash Flow | 8.63M | 2.60M | -5.00K | -73.00K | 9.47M | 2.47M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $17.67M | ― | -105.72% | ― | 0.09% | 51.09% | |
44 Neutral | $21.76M | ― | -262.03% | ― | 2.65% | 70.21% | |
42 Neutral | $10.96M | 0.44 | ― | ― | -73.36% | ― | |
42 Neutral | $14.20M | ― | -195.48% | ― | -40.47% | 96.14% | |
41 Neutral | $22.30M | ― | ― | ― | 15.00% | 71.57% | |
40 Underperform | $24.05M | ― | ― | ― | -26.49% | -91.23% |
On May 14, 2025, Iridex Corporation received a notification of non-compliance from Nasdaq due to not meeting the continued listing standards based on its quarterly report for the period ending March 29, 2025. However, by August 27, 2025, the company had regained compliance with the Nasdaq listing standards by meeting the minimum stockholders’ equity requirement of $2,500,000, as confirmed by Nasdaq’s formal notification. This resolution ensures Iridex’s continued listing on the Nasdaq Capital Market, closing the matter and stabilizing its market position.
The most recent analyst rating on (IRIX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Iridex stock, see the IRIX Stock Forecast page.
The recent earnings call for Iridex presented a mixed sentiment, highlighting both positive strides in revenue growth and cost reduction, alongside challenges such as declining gross margins and regional sales issues. While the company successfully implemented efficiency measures and reported a positive adjusted EBITDA, it continues to face market challenges and a net loss.
Iridex Corporation is a global leader in the development and marketing of innovative laser-based medical systems for treating glaucoma and retinal diseases, utilizing its proprietary MicroPulse technology to offer safe and effective solutions in the ophthalmology market.